Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia.

@article{Groot1998CosteffectivenessAQ,
  title={Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia.},
  author={Carin A. Uyl-de Groot and Bob L{\"o}wenberg and Edo Vellenga and Stefan Suciu and Roel Willemze and Frans F. H. Rutten},
  journal={British journal of haematology},
  year={1998},
  volume={100 4},
  pages={629-36}
}
We conducted a prospective, randomized, multicentre clinical trial comparing the effects and costs of GM-CSF as an adjunct to intensive chemotherapy in elderly patients with acute myeloid leukaemia (AML). The patients were randomized to either daunomycin-cytosine arabinoside (control arm: n = 161) or daunomycin-cytosine arabinoside with GM-CSF (GM-CSF arm: n = 157). The primary end-point was the effect of GM-CSF on the percentage of complete remissions (CR). Survival duration, disease-free… CONTINUE READING